Showing results (1-10 of 308) with videos related to
Sort By:
Pageof 31
Pathologie-Biologie|August 12, 2006
The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disordersJ J Kiladjian, N Casadevall, W Vainchenker, et al.Cellular and Molecular Life Sciences : CMLS|November 30, 2006
Oncogenic mechanisms in myeloproliferative disordersF Delhommeau, D F Pisani, C James, et al.Oncogene|July 26, 2011
JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasmsM Nakatake, B Monte-Mor, N Debili, et al.The Journal of Clinical Investigation|September 1, 1991
Autocrine stimulation by erythropoietin and autonomous growth of human erythroid leukemic cells in vitroM T Mitjavila, J P Le Couedic, N Casadevall, et al.Blood|February 15, 1996
Missense mutation of the erythropoietin receptor is a rare event in human erythroid malignanciesJ P Le Couedic, M T Mitjavila, J L Villeval, et al.Blood|December 15, 1992
Granulocyte-macrophage colony-stimulating factor and erythropoietin act competitively to induce two different programs of differentiation in the human pluripotent cell line UT-7O Hermine, P Mayeux, M Titeux, et al.Annales Pharmaceutiques Francaises|January 1, 1996
[Physiology of eryhtropoietin and its therapeutic use]N CasadevallNouvelle Revue Francaise D'Hematologie|April 1, 1994
Determination of serum erythropoietin. Its value in the differential diagnosis of polycythemiasN CasadevallPageof 31